Takeda pivotal trial win improves convenience for PID patients relative to HyQvia
A pivotal study of a Takeda primary immunodeficiency disease (PID) asset has hit its primary endpoint, demonstrating pharmacokinetic (PK) comparability between...
A pivotal study of a Takeda primary immunodeficiency disease (PID) asset has hit its primary endpoint, demonstrating pharmacokinetic (PK) comparability between the asset and HyQvia, which was approved to treat PID in 2014.